about
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAARTChanges in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) studySubcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort studyHIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodiesMeta-analysis of risk factors for cutaneous melanoma: II. Sun exposure.Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patientsMolecular characterization of HIV-1 subtype C gp-120 regions potentially involved in virus adaptive mechanisms.HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trialHIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trialDevelopment of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine.Building up a collaborative network for the surveillance of HIV genetic diversity in Italy. A pilot study.Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II).Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study.Evidence for the association of human papillomavirus infection and cutaneous squamous cell carcinoma in immunocompetent individuals.Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing—remitting multiple sclerosisCognitive impairment and its relation with disease measures in mildly disabled patients with relapsing–remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) studyBDNF Val66Met polymorphism and brain volumes in multiple sclerosisDevelopment of the Italian Version of the National Institutes of Health Stroke Scale
P50
Q28476094-45944955-B380-4A6B-901A-4DCA3AFE1EE8Q31038347-F76709F9-AF28-478B-910D-8C7089DECD0FQ31141962-4FE2A07E-7E9D-4AF8-B8F4-1698703A6002Q33864926-BE9B4B5A-5847-405C-940E-C0EA64AB17BEQ34477471-DBD6F347-64EE-478A-B1F6-F4B64925C144Q34553701-35FBD541-F491-4D82-803B-734B430FF6B1Q35009131-C3EC22AA-57F7-4762-A738-124038E885F8Q35161426-DC19A03B-CCC6-4790-9AAC-1B18087860C2Q35552889-84E90157-7B9B-42DF-8FAC-F8B878134C11Q36986644-437B04A9-2733-43CE-811D-313563A3709EQ38533881-E9AF8369-47EC-42E8-AC6D-A7FD3C16D01FQ40090766-4CDE2ACC-8987-4AB1-A65D-46424C464509Q48582785-34C22CEC-BB60-4806-9434-CDEFA40E2D81Q48687986-5769E21B-0DBE-493D-95ED-09D727BEF2B1Q53858458-74572B7B-11B0-443F-BD31-860403DCE80FQ59389220-60D516E6-9EEC-4D25-96E9-364678BF9494Q59389222-40C8E0BE-DE5E-4B55-B62E-7CB27CF90226Q61651981-479B46A2-3923-42B9-8D60-244726467D9CQ61651984-1B8933A4-26AB-44B1-9667-92B5B5764F87
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Orietta Picconi
@ast
Orietta Picconi
@en
Orietta Picconi
@es
Orietta Picconi
@nl
Orietta Picconi
@sl
type
label
Orietta Picconi
@ast
Orietta Picconi
@en
Orietta Picconi
@es
Orietta Picconi
@nl
Orietta Picconi
@sl
prefLabel
Orietta Picconi
@ast
Orietta Picconi
@en
Orietta Picconi
@es
Orietta Picconi
@nl
Orietta Picconi
@sl
P1053
L-4613-2016
P106
P21
P31
P3829
P496
0000-0003-3626-9952